Respiratory Syncytial Virus Diagnostics Market Report Scope & Overview:

The Respiratory Syncytial Virus Diagnostics Market was valued at USD 6.73 Billion in 2025 and is expected to reach USD 11.86 Billion by 2035, growing at a CAGR of 5.83% from 2026–2035.

The Respiratory Syncytial Virus (RSV) Diagnostics Market is growing owing to increased global incidence rate of respiratory syncytial virus infections, particularly in children, elderly, and immuno-compromised individuals. Increasing awareness related to early detection and effective treatment is fueling the need for advanced diagnostic systems. The advent of molecular diagnostic tests such as RT-PCR and rapid antigen tests is contributing to improved test precision and faster results. Enhanced healthcare infrastructure and increased hospitalization rates of patients are also supporting the growth in this market. Further, technological advancements in products coupled with government initiatives are expected to aid market growth.

According to the World Health Organization, RSV causes an estimated 33 million acute lower respiratory tract infections annually in young children worldwide. It also leads to approximately 3.6 million hospitalizations and over 100,000 deaths each year among children under five, highlighting the critical need for early and accurate diagnostic solutions globally.

Respiratory Syncytial Virus Diagnostics Market Size and Forecast:

• Market Size in 2026E: USD 7.12 Billion

• Market Size by 2035: USD 11.86 Billion

• CAGR: 5.83% from 2026 to 2035

• Fastest Growing Region: Asia Pacific

• Largest Region: North America

Respiratory Syncytial Virus Diagnostics Market Trends:

• Rising prevalence of Respiratory Syncytial Virus (RSV) infections, particularly among infants, elderly populations, and immunocompromised patients, driving demand for rapid and accurate diagnostic solutions

• Growing adoption of molecular diagnostic techniques such as RT-PCR and nucleic acid amplification tests (NAATs) enabling high-sensitivity and early detection of RSV

• Increasing focus on point-of-care testing solutions to enable faster clinical decision-making and reduce hospital burden during seasonal outbreaks

• Expanding integration of multiplex respiratory panels allowing simultaneous detection of RSV along with influenza and other respiratory pathogens

• Rising healthcare investments and strengthened surveillance programs supporting early diagnosis, outbreak control, and improved patient management outcomes

U.S. RSV Diagnostics Market Outlook:

The Respiratory Syncytial Virus Diagnostics Market was valued at USD 1.94 Billion in 2025 and is expected to reach USD 3.06 Billion by 2035, growing at a CAGR of 4.67% from 2026–2035.

The United States leads North American RSV diagnostics revenues through the world’s most comprehensive respiratory pathogen surveillance infrastructure, the largest NICU and paediatric ICU institutional procurement base for molecular RSV diagnostics, and the progressive implementation of RSV maternal immunisation programme monitoring creating structured surveillance procurement. Abbott, Roche Diagnostics, bioMérieux, and Hologic sustain U.S. market leadership through their FDA-cleared molecular and rapid antigen RSV diagnostic platforms whose hospital procurement and POC channel penetration define domestic market standards.

According to the U.S. Centers for Disease Control and Prevention, RSV leads to approximately 58,000–80,000 hospitalizations annually among children under 5 in the United States, highlighting its significant pediatric disease burden. It also results in 60,000–160,000 hospitalizations annually among adults aged 65 and older, emphasizing the need for effective diagnostic and monitoring solutions.

Respiratory Syncytial Virus Diagnostics Market Segment Analysis:

• By Test Type, Molecular Diagnostics / RT-PCR segment dominated the Respiratory Syncytial Virus Diagnostics Market in 2025 with 46% share; Rapid Antigen Detection Tests segment is the fastest growing segment.

• By Product, Kits & Reagents segment dominated the market in 2025 with 63% share; Instruments & Analysers segment is the fastest growing segment.

• By End User, Hospitals segment dominated the market in 2025 with 41% share; Point-of-Care Settings segment is the fastest growing segment.

By Test Type, molecular diagnostics & RT-PCR segment dominates the market, while rapid antigen detection tests segment is the fastest-growing segment

Molecular diagnostics and RT-PCR dominated the Respiratory Syncytial Virus Diagnostics Market in 2025 owing to their high accuracy and precision along with the ability to detect the genetic material of viruses in their early stages of infection. Such tests have gained widespread acceptance in hospitals and diagnostic centers as accurate clinical decision-making is possible through them. The increasing prevalence of RSV infections, high demands for efficient diagnostic instruments, and the presence of well-established laboratory facilities have added to their domination. RT-PCR is considered the gold standard for detecting respiratory viruses across the globe.

Rapid antigen detection tests are the fastest growing segment due to their speed of diagnosis, usability, and decentralized diagnostic capacity. These tests yield results in minutes, thus being very effective in emergency situations and in outpatients clinics. The rising need for POC diagnostics, frequent RSV outbreaks, and fast clinical decision-making are all factors behind the growing popularity of such tests. Affordability and availability of these tests drive their growth even further.

By Product, kits & reagents segment dominates the market, while instruments & analysers segment is the fastest-growing segment

Kits and reagents dominated the market in 2025 owing to their need in every diagnosis test conducted. These form an integral part of all tests performed via either antigen or molecular technology making them an indispensable factor in terms of accuracy and efficiency in the testing process. High volume testing done by laboratories and hospitals, along with repeat tests required for patients, makes their need constant and hence ensures their dominant status within the RSV diagnostics industry.

Instruments and analysers are the fastest growing segment owing to increased investments in state-of-the-art diagnostic infrastructure. The rising usage of high throughput molecular test platforms in hospitals and laboratories is leading to an increased demand for this category of products. In addition to this, technological innovations in diagnostic equipment, emphasis on speed and precision in diagnosis, and increasing networks of laboratories are boosting the market’s growth potential.

By End User, hospitals segment dominates the market, while point-of-care settings segment is the fastest-growing segment

Hospitals dominated the Respiratory Syncytial Virus Diagnostics Market in 2025 owing to the high patient influx, presence of advanced diagnostics facilities, and the need for critical care. Hospitals are the key locations where the RSV test is performed, particularly in cases related to children and senior citizens. Moreover, hospitals are dominated by the presence of expert medical professionals and molecular diagnostics techniques. Growing number of hospitalizations amid an RSV outbreak is also contributing to growth.

Point-of-care settings are the fastest growing segment due to the increase in the demand for fast, convenient, and decentralized diagnosis. Point of care allows rapid RSV diagnosis without the need for centralized laboratories. An increase in the trend of early diagnosis, outpatient services, and use of mobile diagnostic instruments is propelling the market. Convenience, cost-efficiency, and fast clinical decision-making are fueling their popularity.

Regional Analysis:

North America RSV Diagnostics Market Insights

North America led the global RSV Diagnostics Market in 2025 with a 41.18% revenue share through its advanced healthcare infrastructure, high adoption of molecular and rapid diagnostic technologies, and significant government investment in RSV surveillance and vaccine programme monitoring. The United States accounts for approximately 82.5% of North American revenues through Abbott, Roche Diagnostics, bioMérieux, and Hologic’s FDA-cleared RSV diagnostic platform commercial leadership.

According to the National Institutes of Health, RSV is a major driver of pediatric respiratory illness requiring clinical testing and hospitalization, reinforcing the importance of early and accurate diagnostic methods in managing disease outcomes.

Canada contributes supplementary North American revenues through its universal healthcare system’s hospital RSV molecular diagnostic procurement, the growing RSV surveillance programme’s testing investment, and the progressive expansion of RSV rapid testing in paediatric primary care settings supporting early RSV case identification for contact management and prophylaxis programme administration.

Europe RSV Diagnostics Market Insights

Europe is a significant RSV diagnostics market where the European Medicines Agency’s approval of nirsevimab RSV prophylaxis creating national immunisation programme monitoring, the European RSV vaccination campaign’s surveillance requirements, and the growing clinical recognition of RSV’s burden in elderly adults create structured testing demand growth. Germany accounts for approximately 22.4% of European revenues through its large hospital RSV molecular diagnostic infrastructure and Roche Diagnostics’ European commercial leadership.

According to the European Centre for Disease Prevention and Control, RSV is a major seasonal respiratory virus that significantly contributes to hospital admissions among infants and elderly populations, reinforcing the need for timely diagnosis and effective surveillance systems.

The United Kingdom’s NHS RSV vaccination programme surveillance, France’s paediatric RSV hospitalisation monitoring, and Scandinavian countries’ comprehensive respiratory pathogen surveillance systems collectively sustain European RSV diagnostics market development. European IVDR’s updated conformity requirements for RSV diagnostic test registration create commercial barriers that favour established molecular platform providers over novel entrants.

Asia Pacific RSV Diagnostics Market Insights

Asia Pacific is the fastest-growing regional RSV diagnostics market, driven by the world’s largest paediatric population creating the highest RSV hospitalisation burden, expanding healthcare infrastructure investment enabling RSV diagnostic access in previously undiagnosed patient populations, and growing government RSV surveillance programme implementation. China accounts for approximately 38.5% of Asia Pacific revenues through its large paediatric hospital RSV diagnostic procurement and the growing clinical awareness of RSV’s hospitalisation burden.

According to the World Health Organization Western Pacific Region, respiratory infections including RSV are a major cause of pediatric hospital admissions, highlighting the ongoing burden on healthcare systems and the need for early and accurate diagnostic testing.

India’s rapidly expanding hospital infrastructure’s growing RSV molecular diagnostic adoption, Japan’s comprehensive respiratory pathogen surveillance programme’s RSV testing procurement, and South Korea’s advanced diagnostic infrastructure create secondary Asia Pacific RSV market demand.

According to the Indian Council of Medical Research, respiratory viral surveillance programs are expanding across major hospitals in India, supporting improved detection, monitoring, and response to respiratory infections such as RSV.

MEA & Latin America RSV Diagnostics Market Insights

The UAE leads MEA revenues at approximately 22.8% through its advanced hospital diagnostic infrastructure, the large expatriate paediatric population creating RSV diagnostic demand, and the growing adoption of multiplex respiratory panel testing in UAE health centres. Saudi Arabia’s comprehensive hospital RSV surveillance and the Kingdom’s neonatal care programme’s RSV testing requirements create growing regional demand.

Brazil leads Latin American revenues at approximately 43.8% through its large paediatric hospital sector’s RSV diagnostic procurement, the PAHO’s RSV surveillance programme’s testing investment, and the growing primary care diagnostic capacity creating RSV rapid test access outside hospital settings. Mexico and Colombia contribute growing secondary demand through their expanding hospital infrastructure and respiratory pathogen surveillance.

Market Dynamics:

Growth Drivers: RSV prophylaxis and vaccine approval creating surveillance programmes and multiplex respiratory panel adoption expanding RSV testing volume

The RSV diagnostics market’s growth is driven by the commercial launch of RSV prophylaxis products whose population-level deployment creates clinical monitoring and effectiveness surveillance testing programmes generating above-baseline RSV diagnostic procurement. Nirsevimab’s approval for all infants’ RSV season prophylaxis and the RSV maternal vaccine’s approval for third-trimester maternal immunisation collectively create paediatric RSV surveillance programmes whose diagnostic component represents structured institutional and public health testing procurement. Each country that implements RSV immunisation programme creates epidemiological surveillance RSV testing requirements that sustain above-endemic-season diagnostic volume.

Restraints: Seasonal RSV testing volume concentration and lower-income market rapid test affordability constraining year-round procurement consistency

RSV diagnostic testing’s strong seasonality, concentrated in the Northern Hemisphere RSV season from October through March and the Southern Hemisphere season from April through September, creates procurement and revenue seasonality that creates management challenges for RSV diagnostic manufacturers and laboratory system planners whose capital equipment investment and reagent inventory must accommodate peak-season demand without incurring excessive off-season carrying cost. Each RSV diagnostic platform whose revenue concentration in 5 to 6 seasonal months creates annual budget cycles where capital justification requires demonstrating sufficient peak-season test volume to amortise system cost.

Opportunities: Geriatric RSV diagnostic expansion and combined RSV-influenza-COVID multiplex panel growth creating premium RSV testing market categories

Geriatric RSV diagnostics represents a structurally growing market expansion whose clinical rationale is supported by the growing evidence base documenting RSV’s significant morbidity in adults over 65 years whose community-acquired respiratory illness hospitalisation from RSV is substantially underdiagnosed in clinical practice relative to true RSV incidence. Each hospital geriatrics ward that adds RSV molecular testing to its respiratory illness investigation protocol and each adult infectious disease clinician who includes RSV in their differential diagnosis creates geriatric RSV diagnostic volume growth whose aggregate across the ageing global population creates an expanding adult testing market above the established paediatric diagnostic base.

Recent Developments:

• 2025: SEKISUI Diagnostics launched its 15-minute CLIA-waived OSOM RSV test for point-of-care use in physician offices, urgent care centres, and retail health clinics, enabling rapid RSV diagnosis without laboratory infrastructure for same-visit treatment decision support.

• 2024: Roche Diagnostics received FDA clearance for its cobas Liat RSV assay providing 20-minute molecular RSV detection at point-of-care settings including emergency departments, enabling rapid molecular RSV diagnosis with same-visit clinical decision support capability.

• 2024: Abbott launched its ID NOW RSV 2 isothermal amplification assay achieving 15-minute RSV detection with improved sensitivity over its first-generation platform for the ID NOW rapid molecular diagnostics system deployed across hospital and point-of-care settings.

RSV Diagnostics Market Key Players are:

• Abbott Laboratories

• Roche Diagnostics

• Siemens Healthineers

• Danaher Corporation

• Cepheid

• bioMérieux

• QuidelOrtho Corporation

• Thermo Fisher Scientific

• Becton Dickinson (BD)

• Hologic, Inc.

• DiaSorin S.p.A.

• Luminex Corporation

• Seegene Inc.

• GenMark Diagnostics

• F. Hoffmann-La Roche Ltd

• Abbott Rapid Diagnostics

• Meridian Bioscience

• Trinity Biotech

• Co-Diagnostics, Inc.

• Qiagen N.V.

Respiratory Syncytial Virus Diagnostics Market Report Scope: